|Day Low/High||14.74 / 14.89|
|52 Wk Low/High||11.68 / 19.19|
From very different sectors, all three of these names will report earnings this week.
From very different sectors, all three report earnings next week.
The key thing about investing mistakes is taking the time to learn from them.
The key thing about investing mistakes it taking the trouble to learn from them.
Alerian MLP offers way to play a rebound for the group while yielding close to 9%.
A master limited partnership whose price was mistakenly hurt by the FERC tax ruling offers big upside.
The path of least resistance on ETE is higher -- go long here.
A trade at $20 will be a triple-top breakout and give us a potential upside price objective of $30.
Commodity stocks that look best positioned for a reversal higher this month
Natural-gas firm's technicals look very energetic.
Several major pipeline companies in the U.S. should benefit from renewed investor interest following Donald Trump's win, says Mizuho.
Not too long ago, it was best to stay from foreign assets and energy exposure. That was then, this is now.
Recovery after a plunge seems to be the pattern for the quarter.
Shares of Energy Transfer Equity are higher on reports that Williams Cos. is open to changing the terms of the company's planned $20 billion merger.
Jim Cramer and Jack Mohr dispel the attack from a recent report.
ETP is truly distinct from its brethren, operating in a rare area experiencing demand.
Dan Dicker, Energy contributor at TheStreet, recants his recommendation of Kinder Morgan (KMI) that he made last week at $21 a share.
Oneok Partners and Williams Partners look considerably more attractive than a month ago.
But first, a look at the JPMorgan Alerian MLP ETN.
Jim Cramer, portfolio manager of TheStreet's Action Alerts Plus and host of CNBC's 'Mad Money,' sees a selective Santa Claus rally on Wall Street this year.
The MLP space is a good example of how markets turn.
Highly aggressive, short-term traders should focus on MPLs.
Valeant Pharmaceuticals (VRX) tumbled Monday as Congressional Democrats asked to subpoena the company for documents related to drug price increases.
Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.
But even in this downswing, there may be opportunities, Williams among them.